Adjuvant therapy in pancreatic cancer

Table 4 Neoadjuvant therapy for pancreatic cancer

Series	Year	Number	Regimen	Resection rate		Positive resection margin (n)	Median survival (months)	Actuarial survival (%)
				n	%			3 year	5 year
Ishikawa et al[70]	1994	23	EBRT	17/23	74				22
Coia et al[71]	1994	27	EBRT + 5-FU + MMC	13/27	48	0/13	16	43
Staleyet al[72]	1996	39	EBRT + 5-FU + IORT	39/39	100	7/39	19		19 (4 year)
Spitz et al[73]	1997	41	EBRT + 5-FU	41/91	51	5/41	19.2
Hoffman et al[74]	1998	53	EBRT + 5-FU + MMC	24/53	45		15.7
White et al[75]	1999	25	5-FU + EBRT + MMC + CPP	5/25	20
Wanebo et al[76]	2000	14	5-FU + EBRT + CPP	9/14	64
Snady et al[77]	2000	68	EBRT + 5-FU + STREP + CPP	20/68	29		32	32
				48 NR	71		21	13

EBRT = external beam radiotherapy; 5-FU = 5-fluorouracil; MMC = mitomycin C; IORT = intraoperative radiotherapy; STP = streptozocin; CDDP = cisplatinum; FA = folinic acid; DPD = dipyridamole; n = number; CPP = cisplatin; NR = not resectable.